Mood Disorders News

Onset of premenstrual dysphoric disorder symptoms was associated with estradiol/progesterone levels changing from low to high, according to recent findings.

Findings from two phase 3 clinical trials indicated efficacy, safety and tolerability of Rexulti for agitation in individuals with Alzheimer’s disease.

Real-time functional MRI neurofeedback training that targeted the amygdala increased the percentage of specific memories recalled and decreased depressive symptoms among adults with major depressive disorder.

Recent findings indicated sleep quality affected emotion regulation in individuals with anxiety or depression disorders.

At the American Academy of Neurology annual meeting, researchers presented long-term efficacy and safety data supporting the recent FDA approval of Ingrezza for tardive dyskinesia in adults.

Moderate-severe menopausal vasomotor symptoms were independently and significantly associated with moderate-severe depressive symptoms in women aged 40 to 65 years.

Ketamine had no added benefit on neuropsychological and clinical outcomes in depression when added to electroconvulsive therapy, according to recent findings.

Recent findings indicated that children exposed to serotonergic antidepressants in utero did not have increased risk for autism compared with unexposed children.

Analysis of national data indicated modest and time-dependent associations between mental and behavioral disorders and increased risk for Alzheimer’s disease.

The FDA recently approved Ingrezza capsules for treatment of tardive dyskinesia in adults.